Jefferies Financial Group Reaffirms Buy Rating for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating reissued by investment analysts at Jefferies Financial Group in a research note issued to investors on Friday, Digital Look reports. They presently have a GBX 2,025 price target on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 27.92% from the stock’s previous close.

Several other research analysts have also recently commented on the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a research note on Friday, August 7th. Citigroup increased their price target on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Berenberg Bank upped their target price on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of GBX 2,085.83.

Hikma Pharmaceuticals Stock Down 2.6%

Shares of Hikma Pharmaceuticals stock traded down GBX 42 during trading hours on Friday, reaching GBX 1,583. 353,087 shares of the company were exchanged, compared to its average volume of 4,575,345. Hikma Pharmaceuticals has a 1 year low of GBX 1,187 and a 1 year high of GBX 1,865. The stock’s fifty day moving average is GBX 1,602.32 and its 200 day moving average is GBX 1,475.50. The company has a debt-to-equity ratio of 77.57, a quick ratio of 1.27 and a current ratio of 1.98. The firm has a market cap of £3.28 billion, a PE ratio of 8.99, a PEG ratio of 2.38 and a beta of 0.66.

Insider Transactions at Hikma Pharmaceuticals

In related news, insider Tobias Hestler acquired 7,500 shares of Hikma Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of GBX 1,648 per share, with a total value of £123,600. 22.26% of the stock is owned by company insiders.

Hikma Pharmaceuticals News Summary

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Jefferies reaffirmed its “buy” rating on Hikma and set a GBX 2,025 price target, implying potential upside from recent trading levels. Tickerreport.com report
• Positive Sentiment: Hikma has appointed Rebecca Hall, formerly a finance executive at ViiV Healthcare, as chief financial officer and executive director. Her experience in the pharmaceuticals sector could reassure investors about the company’s financial management. Hikma appoints Rebecca Hall as CFO and executive director
• Positive Sentiment: One market report indicated Hikma stock was trading higher ahead of the open, suggesting some investors viewed the broker support and CFO appointment favorably. Hikma stock gains ahead of the open
• Neutral Sentiment: Current CFO Khalid Nabilsi is stepping down, with Hall named as his successor. The transition is not reported as performance-related, but investors may monitor execution and continuity during the handover. Hikma CFO succession report
• Negative Sentiment: The concentration of reports on CFO and board changes may be contributing to near-term uncertainty, helping explain why the shares have traded lower despite the favorable Jefferies view.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.